CN101810591A - Mangiferin dispersible tablets and preparation method thereof - Google Patents
Mangiferin dispersible tablets and preparation method thereof Download PDFInfo
- Publication number
- CN101810591A CN101810591A CN 201010147681 CN201010147681A CN101810591A CN 101810591 A CN101810591 A CN 101810591A CN 201010147681 CN201010147681 CN 201010147681 CN 201010147681 A CN201010147681 A CN 201010147681A CN 101810591 A CN101810591 A CN 101810591A
- Authority
- CN
- China
- Prior art keywords
- mangiferin
- dispersible tablets
- chimonin
- weight portions
- crospolyvinylpyrrolidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of medicaments, and discloses mangiferin dispersible tablets, which comprise the following components in part by weight: 20 to 300 parts of mangiferin, 50 to 250 parts of lactose, 50 to 300 parts of microcrystalline cellulose, 10 to 100 parts of crosslinked polyvinylpyrrolidone, 1 to 50 parts of polyvidone, 1 to 10 parts of magnesium stearate and 1 to 20 parts of superfine silica powder. The invention also provides a preparation method for the mangiferin dispersible tablets. The mangiferin dispersible tablets have the advantages of attractive appearance, good mouthfeel, good dispersion state, quick medicament dissolution and high bioavailability. The preparation method has the advantages of simplified process, low production cost, easy scale production and good industrial application prospect.
Description
Technical field
The present invention relates to field of medicaments, be specifically related to a kind of mangiferin dispersible tablets and preparation method thereof.
Background technology
Chimonin (mangiferin) is the natural polyphenol compounds that extraction in the plant, separation and purification obtain, molecular formula: C
19H
18O
11, molecular weight: 422.Its chemical constitution is as follows:
The leaf of Anacardiaceae plant mango (Mangifera indica.L), the leaf of almond (Mangiferapersiciformis), fruit, bark, gentianaceae plant Northeastern Radix Gentianae (Gentianamanshurica Kitag), west, river Herba Swertiae bimaculatae (Swertia mussotii Franch), the liliaceous plant Rhizoma Anemarrhenae (Anemarrhena asphodeloides Bge.), Polypodiaceae plant Herba Pyrrosiae Calvatae [Pyrrosiaclvata (Bak) Chin], the aerial parts of thymelaeceae trees (Gnidia involucrata), Herba Hyperici perforati [St.John ' wort (H ypericum perforatum L.)], the root of syringa reticulata var mandshurica [Salacia reticulata (SRE)] all contains chimonin (referring to Li Haowen, Deng Jiagang, Deng Jing. chimonin foreign study progress. the journal .2003 of Colleges Of Traditional Chinese Medicine Of Guangxi, 6 (4): 62-66).
The pharmacological research of chimonin shows that it has multiple biological activity, as antitussive, eliminate the phlegm, antiinflammatory, analgesia, antioxidation, antitumor, antibiotic, antiviral, blood sugar lowering, hepatic cholagogic, immunomodulating be (referring to Deng Jiagang, Cao Chunhui. 30 years research overviews of Folium mangiferae and chimonin. the journal .2003 of Colleges Of Traditional Chinese Medicine Of Guangxi, 6 (2): 5-49; Liao Hongli, Wu Qiuye, leaf light, Cai Lingzhi. chimonin pharmacological research progress. Tianjin pharmacy .2005,17 (2): 50-52.), can also be used for gout and hyperuricemia (referring to Chinese patent CN101214254A, the new purposes of mangiferin compounds) etc.
Dispersible tablet be development in recent years get up a kind of in water the rapid homodisperse quick-effective preparation of disintegrate because its distinctive advantage more and more is subjected to people's attention.2000 editions two radicals by which characters are arranged in traditional Chinese dictionaries of Chinese Pharmacopoeia have recorded this dosage form.Dispersible tablet has the following advantages: good dispersing state, disintegration time are lacked, the medicine stripping is rapid; Absorption is fast, bioavailability is high; Taking convenience can be swallowed, chews, contain and suck or with taking after the aqueous dispersion, especially is fit to child, old man and the patient of the difficulty of swallowing uses.
Because chimonin is poorly soluble, water-soluble hardly, bioavailability is low, therefore has been subjected to very big restriction on the dosage form selection of medicine, has influenced its clinical practice as oral medicine to a certain extent.
Summary of the invention
It is poorly soluble to the present invention is directed to chimonin, water-soluble hardly, and the defective that bioavailability is low provides a kind of mangiferin dispersible tablets.Mangiferin dispersible tablets of the present invention can increase the dissolubility of chimonin effectively, improves bioavailability, thereby brings into play its drug effect better.
In order to realize the foregoing invention purpose, the invention provides following technical scheme:
A kind of mangiferin dispersible tablets, its component is: chimonin 20～300 weight portions, lactose 50～250 weight portions, microcrystalline Cellulose 50～300 weight portions, crospolyvinylpyrrolidone 10～100 weight portions, polyvidone 1～50 weight portion, magnesium stearate 1～10 weight portion, micropowder silica gel 1～20 weight portion.
As preferably, described mangiferin dispersible tablets contains 25～200 weight portion chimonins.
The present invention also provides the preparation method of above-mentioned mangiferin dispersible tablets, comprises following steps:
Step 1: raw material is sieved respectively, take by weighing lactose, microcrystalline Cellulose, crospolyvinylpyrrolidone, polyvidone and mixing;
Step 2: add the chimonin mixing;
Step 3: add magnesium stearate, micropowder silica gel mixing, direct compression promptly gets mangiferin dispersible tablets of the present invention.
The present invention also provides a kind of mangiferin dispersible tablets, and its component is: chimonin 20～300 weight portions, lactose 50～250 weight portions, mannitol 50～300 weight portions, crospolyvinylpyrrolidone 10～100 weight portions, magnesium stearate 1～10 weight portion, micropowder silica gel 1～20 weight portion.
As preferably, described mangiferin dispersible tablets contains 25～200 weight portion chimonins.
The present invention also provides the preparation method of above-mentioned mangiferin dispersible tablets, comprises following steps:
Step 1: raw material is sieved respectively, take by weighing chimonin, lactose, mannitol adds 50% crospolyvinylpyrrolidone mixing of described consumption;
Step 2: make wetting agent system soft material with 95% ethanol, cross 18～24 mesh sieves and granulate, wet granular is dry under 50～80 ℃ of conditions;
Step 3: with 16～40 mesh sieve granulate, add 50% crospolyvinylpyrrolidone, magnesium stearate, micropowder silica gel mixing of described consumption, tabletting promptly gets mangiferin dispersible tablets of the present invention.
As preferably, described the sieving of step 1 is to cross 100 mesh sieves in the preparation method of two kinds of mangiferin dispersible tablets.
Dissolution (Dissolution rate) also claim dissolution rate, is meant under specified solvent and condition the speed and the degree of medicine stripping from solid preparations such as tablet, capsule, granule.The process of measuring the solid preparation dissolution is called the dissolution test, and it is a kind of disintegrate of oral solid formulation in gastrointestinal tract and in vitro tests method of stripping simulated.The drug dissolution inspection is a kind of effective means of estimating preparation quality and technological level, the difference that can reflect crystal formation, granularity, prescription composition, adjuvant kind and character, the production technology etc. of principal agent, it also is a kind of effective standard of estimating the preparation active component bioavailability and the preparation uniformity, can effectively distinguish the difference with a kind of drug bioavailability, be one of drug quality control essential items for inspection.
2 minutes dissolutions of mangiferin dispersible tablets of the present invention can reach more than 98%, promptly finish disintegrate in 3 minutes, and ordinary tablet just begins stripping after 5 minutes, and the accumulation dissolution was about 50% of dispersible tablet in 7 minutes.
Mangiferin dispersible tablets of the present invention and preparation method thereof has the following advantages:
1, chimonin and specific speed collapse after agent and good excipient make up in proportion, and dispersing uniformity is good, has improved bioavailability.
2, mangiferin dispersible tablets of the present invention can rapid disintegrate form homogeneous dispersion in water, the stripping that helps medicine absorbs, and has reduced disintegration time, has accelerated the absorption of effective ingredient, ordinary tablet was disintegrate in 5 to 15 minutes, and mangiferin dispersible tablets of the present invention was promptly finished disintegrate in 3 minutes.
3, mangiferin dispersible tablets taking convenience of the present invention can be swallowed, chews, contain and suck or with taking after the aqueous dispersion.
4, preparation method work simplification of the present invention, production cost is lower, easily large-scale production.
The specific embodiment
The invention discloses mangiferin dispersible tablets and preparation method thereof, those skilled in the art can use for reference this paper content, suitably improve technological parameter and realize.Special needs to be pointed out is that all similarly replace and change apparent to those skilled in the art, they all are regarded as being included in the present invention.Method of the present invention and application are described by preferred embodiment, the related personnel obviously can change or suitably change and combination methods and applications as herein described in not breaking away from content of the present invention, spirit and scope, realizes and use the technology of the present invention.
The following example is intended to further describe for example the present invention, but is not any restriction to protection domain of the present invention.
Embodiment 1: mangiferin dispersible tablets set of dispense of the present invention is than selecting
Previous experiments result shows that the proportioning of chimonin raw material and adjuvant just can suppress qualified mangiferin dispersible tablets in certain scope, we are optimized experiment to the filler in the mangiferin dispersible tablets component, disintegrating agent, adhesive, and serve as to detect the proportioning test that index has been carried out the mangiferin dispersible tablets component with slice, thin piece outward appearance, dispersing uniformity, dissolution.
(1) consumption of filler is selected
In the present invention, select for use the lactose, microcrystalline Cellulose and the mannitol that are beneficial to the tablet molding as filler, the lactose consumption is during less than 50 weight portions, and the slice, thin piece molding is general, and outward appearance is good, dispersing uniformity 5 minutes, stripping 70%; Consumption is during greater than 250 weight portions, the slice, thin piece forming, and outward appearance is bright and clean complete, dispersing uniformity 8 minutes, stripping 75%.
The microcrystalline Cellulose consumption is during less than 50 weight portions, and the slice, thin piece molding is bad, appearance poor; Consumption is during greater than 300 weight portions, the slice, thin piece forming, and outward appearance is bright and clean complete, dispersing uniformity 7 minutes, stripping 89%.
The mannitol consumption is during less than 50 weight portions, and the slice, thin piece molding is bad, appearance poor; Consumption is during greater than 300 weight portions, the slice, thin piece forming, and outward appearance is bright and clean complete, dispersing uniformity 3 minutes, stripping 97%.
(2) consumption of disintegrating agent is selected
In the present invention, select for use the crospolyvinylpyrrolidone that is beneficial to the disintegration of tablet stripping, the mode that wet-mixed adds in granulating and adopting as disintegrating agent, the crospolyvinylpyrrolidone consumption is during less than 10 weight portions, slice, thin piece is good, and outward appearance is good, dispersing uniformity 8 minutes; Consumption is during greater than 100 weight portions, and the slice, thin piece molding is bad, appearance poor.
(3) consumption of adhesive is selected
In the present invention, select for use the polyvidone that is beneficial to the tablet tabletting as adhesive, the polyvidone consumption is during less than 1 weight portion, and the slice, thin piece molding is poor; Consumption is during greater than 50 weight portions, the slice, thin piece forming, and outward appearance is good, dispersing uniformity 8 minutes, stripping 50%.
The result determines that in conjunction with indexs such as slice, thin piece molding, outward appearance, dispersing uniformity, dissolution and production costs the proportioning amount ranges of adjuvant is: chimonin 20～300 weight portions, lactose 50～250, microcrystalline Cellulose 50～300, mannitol 50～300, crospolyvinylpyrrolidone 10～100, polyvidone 1～50, magnesium stearate 1～10, micropowder silica gel 1～20; Or chimonin 20～300 weight portions, lactose 50～250 weight portions, mannitol 50～300 weight portions, crospolyvinylpyrrolidone 10～100 weight portions, magnesium stearate 1～10 weight portion, micropowder silica gel 1～20 weight portion.
Embodiment 2: mangiferin dispersible tablets of the present invention is carried out dissolution determination
Mangiferin dispersible tablets dissolution determination: measure according to dissolution method (two appendix X of Chinese Pharmacopoeia version in 2005 C, second method).
Instrument and reagent reagent: ZRS-8 type intelligence digestion instrument, Shimadzu UV-2450 ultraviolet-visible spectrophotometer.
Chimonin reference substance: lot number: 111607-200402 is bought by Nat'l Pharmaceutical ﹠ Biological Products Control Institute; Mangiferin dispersible tablets, the development of thigh company limited drug research institute of Kunming pharmacy group, lot number: 20091228.
Dissolution test: get this product, is dissolution medium according to dissolution method (two appendix XC second methods of Chinese Pharmacopoeia version in 2005) with water 900ml, rotating speed is that per minute 75 changes, and operation in accordance with the law is in the time of 30 minutes, taking-up solution filters, precision is measured subsequent filtrate 5ml, puts in the 25ml measuring bottle, adds the stripping medium to scale, shake up, as need testing solution; Other gets the about 5mg of chimonin reference substance, and accurate the title decides, and puts in the 100ml measuring bottle, adds 50% dissolve with methanol solution and is diluted to scale, shakes up, in contrast product solution.Get test sample and reference substance solution respectively, according to ultraviolet visible spectrophotometry (appendix IV A), measure absorbance respectively at the wavelength place of 258nm, calculate every stripping quantity, limit is 85% of a labelled amount, should be up to specification.
Adopt mangiferin dispersible tablets and common chimonin tablet to carry out dissolution relatively
| 45 | 100.2 | 100.1 |
From table the result as seen, the dispersible tablet release rapidly, fully, ordinary tablet just begins stripping after 5 minutes, accumulated dissolution and be about 1 half of dispersible tablet in 7 minutes.Particulate good fluidity in the above-mentioned prescription, hardness is good, and mouthfeel is good, and the dispersing uniformity of tablet meets the requirement of pharmacopeia regulation.
Embodiment 3: the dissolution to mangiferin dispersible tablets of the present invention is measured
Assay: measure according to high performance liquid chromatography (2005 editions two appendix of Chinese Pharmacopoeia)
Instrument and reagent reagent: Shimadzu LC-10ATvp high performance liquid chromatograph: comprise the ShimadzuLC-10ATVP pump, FCV-10ALVP+DGU-12A is combined into online degasser, the SIL-10ADVP automatic sampler, the SPD-M10AVP diode array detector, the CTO-10ASVP column oven, the CLASS-VP work station.Chromatographic column: Zorbax SB-C18 150 * 4.6mm.
Methanol, phosphoric acid are that chromatographic grade, HPLC water are heavily to steam distilled water.
Chimonin reference substance: lot number: 111607-200402 is bought by Nat'l Pharmaceutical ﹠ Biological Products Control Institute; Mangiferin dispersible tablets, the development of thigh company limited drug research institute of Kunming pharmacy group.
Chromatographic condition and system suitability test: with octadecylsilane chemically bonded silica is filler; With methanol-0.1% phosphate aqueous solution) (32: 68) be mobile phase; The detection wavelength is 258nm.Number of theoretical plate calculates by the chimonin peak should be not less than 5000.
The preparation of need testing solution: get 20 of this product, the accurate title, decided porphyrize, get the mixture that is equivalent to contain chimonin 10mg approximately, the accurate title, decide, and puts in the volumetric flask of 50ml, add 50% the about 40ml of methanol, ultrasonic (power 250W, frequency 25kHz) 10 minutes, take out, put coldly, add 50% methanol to scale, shake up, filter, get subsequent filtrate, promptly.
The preparation of reference substance solution: it is an amount of that precision takes by weighing the chimonin reference substance, adds 50% dissolve with methanol, and the solution that every 1ml contains chimonin 0.2mg is made in dissolving and dilution.
Algoscopy: precision weighing is got need testing solution and each 5 μ l of reference substance solution, injects chromatograph of liquid respectively, the record chromatogram, and by external standard method and calculated by peak area, that is, content should be 90.0%-110.0%.
Embodiment 4:
Mangiferin dispersible tablets: 1000
Chimonin 25g
Lactose 200g
Microcrystalline Cellulose 250g
Crospolyvinylpyrrolidone 60g
Polyvidone 15g
Micropowder silica gel 16g
Magnesium stearate 3g
Supplementary material is crossed 100 sieves respectively, take by weighing lactose by recipe quantity, microcrystalline Cellulose, crospolyvinylpyrrolidone, polyvidone mixing; Add the chimonin mixing again; Add magnesium stearate, micropowder silica gel mixing again, tabletting promptly gets mangiferin dispersible tablets of the present invention.
This product is yellowish color chips, carries out dispersing uniformity, dissolution and assay according to the rules, and dispersing uniformity is up to specification, and dissolution is 95%, content 98.0%.
Embodiment 5:
Mangiferin dispersible tablets: 1000
Chimonin 50g
Lactose 150g
Microcrystalline Cellulose 250g
Crospolyvinylpyrrolidone 50g
Polyvidone 5g
Micropowder silica gel 15g
Magnesium stearate 3g
Supplementary material is crossed 100 mesh sieves respectively, take by weighing lactose by recipe quantity, microcrystalline Cellulose, crospolyvinylpyrrolidone, polyvidone mixing; Add the chimonin mixing again; Add magnesium stearate, micropowder silica gel mixing again, tabletting promptly gets mangiferin dispersible tablets of the present invention.
This product is yellowish color chips, carries out dispersing uniformity, dissolution and assay according to the rules, and dispersing uniformity is up to specification, and dissolution is 98%, content 101.0%.
Embodiment 6:
Mangiferin dispersible tablets: 1000
Chimonin 100g
Lactose 200g
Microcrystalline Cellulose 150g
Crospolyvinylpyrrolidone 60g
Polyvidone 15g
Micropowder silica gel 16g
Magnesium stearate 3g
Supplementary material is crossed 100 sieves respectively, take by weighing lactose by recipe quantity, microcrystalline Cellulose, crospolyvinylpyrrolidone, polyvidone mixing; Add the chimonin mixing again; Add magnesium stearate, micropowder silica gel mixing again, tabletting promptly gets mangiferin dispersible tablets of the present invention.
This product is yellowish color chips, carries out dispersing uniformity, dissolution and assay according to the rules, and dispersing uniformity is up to specification, and dissolution is 91%, content 98.0%.
Embodiment 7:
Mangiferin dispersible tablets: 1000
Chimonin 200g
Lactose 100g
Microcrystalline Cellulose 250g
Crospolyvinylpyrrolidone 60g
Polyvidone 15g
Micropowder silica gel 16g
Magnesium stearate 3g
Supplementary material is crossed 100 mesh sieves respectively, take by weighing lactose by recipe quantity, microcrystalline Cellulose, crospolyvinylpyrrolidone, polyvidone mixing; Add the chimonin mixing again; Add magnesium stearate, micropowder silica gel mixing again, tabletting promptly gets mangiferin dispersible tablets of the present invention.
This product is yellowish color chips, carries out dispersing uniformity, dissolution and assay according to the rules, and dispersing uniformity is up to specification, and dissolution is 95%, content 101.0%.
Embodiment 8:
Mangiferin dispersible tablets: 1000
Chimonin 300g
Lactose 50g
Microcrystalline Cellulose 150g
Crospolyvinylpyrrolidone 50g
Polyvidone 15g
Micropowder silica gel 16g
Magnesium stearate 3g
Supplementary material is crossed 100 mesh sieves respectively, take by weighing lactose by recipe quantity, microcrystalline Cellulose, crospolyvinylpyrrolidone, polyvidone mixing; Add the chimonin mixing again; Add magnesium stearate, micropowder silica gel mixing again, tabletting promptly gets mangiferin dispersible tablets of the present invention.
This product is yellowish color chips, carries out dispersing uniformity, dissolution and assay according to the rules, and dispersing uniformity is up to specification, and dissolution is 90%, content 100.0%.
Embodiment 9:
Mangiferin dispersible tablets: 1000
Chimonin 25g
Lactose 250g
Mannitol 150g
Crospolyvinylpyrrolidone 80g
Magnesium stearate 5g
Micropowder silica gel 15g
95% ethanol is an amount of
Supplementary material is crossed 100 mesh sieves respectively, take by weighing chimonin by recipe quantity, lactose, mannitol, crospolyvinylpyrrolidone is half amount of prescription, mixing; Make wetting agent system soft material with 95% ethanol, 18 mesh sieves are granulated, and wet granular is dry under 50～80 ℃ of conditions; With 20 mesh sieve granulate, add second half crospolyvinylpyrrolidone, magnesium stearate, micropowder silica gel mixing, tabletting promptly gets mangiferin dispersible tablets of the present invention.
This product is yellowish color chips, carries out dispersing uniformity, dissolution and assay according to the rules, and dispersing uniformity is up to specification, and dissolution is 99%, content 102.0%.
Embodiment 10:
Mangiferin dispersible tablets: 1000
Chimonin 50g
Lactose 250g
Mannitol 100g
Crospolyvinylpyrrolidone 80g
Magnesium stearate 10g
Micropowder silica gel 15g
95% ethanol is an amount of
Supplementary material is crossed 100 mesh sieves respectively, take by weighing chimonin by recipe quantity, lactose, mannitol, crospolyvinylpyrrolidone is half amount of prescription, mixing; Make wetting agent system soft material with 95% ethanol, 18 mesh sieves are granulated, and wet granular is dry under 50～80 ℃ of conditions; With 20 mesh sieve granulate, add second half crospolyvinylpyrrolidone, magnesium stearate, micropowder silica gel mixing, tabletting promptly gets mangiferin dispersible tablets of the present invention.
This product is yellowish color chips, carries out dispersing uniformity, dissolution and assay according to the rules, and dispersing uniformity is up to specification, and dissolution is 89%, content 98.0%.
Embodiment 11:
Mangiferin dispersible tablets: 1000
Chimonin 100g
Lactose 250g
Mannitol 100g
Crospolyvinylpyrrolidone 80g
Magnesium stearate 10g
Micropowder silica gel 15g
95% ethanol is an amount of
Supplementary material is crossed 100 mesh sieves respectively, take by weighing chimonin by recipe quantity, lactose, mannitol, crospolyvinylpyrrolidone is half amount of prescription, mixing; Make wetting agent system soft material with 95% ethanol, 18 mesh sieves are granulated, and wet granular is dry under 50～80 ℃ of conditions; With 20 mesh sieve granulate, add second half crospolyvinylpyrrolidone, magnesium stearate, micropowder silica gel mixing, tabletting promptly gets mangiferin dispersible tablets of the present invention.
This product is yellowish color chips, carries out dispersing uniformity, dissolution and assay according to the rules, and dispersing uniformity is up to specification, and dissolution is 92%, content 99.2.0%.
Embodiment 12:
Mangiferin dispersible tablets: 1000
Chimonin 200g
Lactose 150g
Mannitol 100g
Crospolyvinylpyrrolidone 80g
Magnesium stearate 10g
Micropowder silica gel 15g
95% ethanol is an amount of
Supplementary material is crossed 100 mesh sieves respectively, take by weighing chimonin by recipe quantity, lactose, mannitol, crospolyvinylpyrrolidone is half amount of prescription, mixing; Make wetting agent system soft material with 95% ethanol, 18 mesh sieves are granulated, and wet granular is dry under 50～80 ℃ of conditions; With 20 mesh sieve granulate, add second half crospolyvinylpyrrolidone, magnesium stearate, micropowder silica gel mixing, tabletting promptly gets mangiferin dispersible tablets of the present invention.
This product is yellowish color chips, carries out dispersing uniformity, dissolution and assay according to the rules, and dispersing uniformity is up to specification, and dissolution is 91%, content 103.0%.
Embodiment 13:
Mangiferin dispersible tablets: 1000
Chimonin 300g
Lactose 150g
Mannitol 100g
Crospolyvinylpyrrolidone 100g
Magnesium stearate 10g
Micropowder silica gel 15g
95% ethanol is an amount of
Supplementary material is crossed 100 mesh sieves respectively, take by weighing chimonin by recipe quantity, lactose, mannitol, crospolyvinylpyrrolidone is half amount of prescription, mixing; Make wetting agent system soft material with 95% ethanol, 18 mesh sieves are granulated, and wet granular is dry under 50～80 ℃ of conditions; With 20 mesh sieve granulate, add second half crospolyvinylpyrrolidone, magnesium stearate, micropowder silica gel mixing, tabletting promptly gets mangiferin dispersible tablets of the present invention.
This product is yellowish color chips, carries out dispersing uniformity, dissolution and assay according to the rules, and dispersing uniformity is up to specification, and dissolution is 90%, content 99.0%.
More than a kind of mangiferin dispersible tablets provided by the present invention and preparation method thereof is described in detail.Used specific embodiment herein principle of the present invention and embodiment are set forth, the explanation of above embodiment just is used for helping to understand method of the present invention and core concept thereof.Should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the principle of the invention, can also carry out some improvement and modification to the present invention, these improvement and modification also fall in the protection domain of claim of the present invention.
The above only is a preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the principle of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (7)
1. mangiferin dispersible tablets, its component is: chimonin 20～300 weight portions, lactose 50～250 weight portions, microcrystalline Cellulose 50～300 weight portions, crospolyvinylpyrrolidone 10～100 weight portions, polyvidone 1～50 weight portion, magnesium stearate 1～10 weight portion, micropowder silica gel 1～20 weight portion.
2. mangiferin dispersible tablets as claimed in claim 1 is characterized in that, chimonin is 25～200 weight portions.
3. according to the preparation method of the described mangiferin dispersible tablets of claim 1, comprise following steps:
Step 1: raw material is sieved respectively, take by weighing lactose, microcrystalline Cellulose, crospolyvinylpyrrolidone, polyvidone and mixing;
Step 2: add the chimonin mixing;
Step 3: add magnesium stearate, micropowder silica gel mixing, direct compression promptly gets mangiferin dispersible tablets of the present invention.
4. mangiferin dispersible tablets, its component is: chimonin 20～300 weight portions, lactose 50～250 weight portions, mannitol 50～300 weight portions, crospolyvinylpyrrolidone 10～100 weight portions, magnesium stearate 1～10 weight portion, micropowder silica gel 1～20 weight portion.
5. mangiferin dispersible tablets as claimed in claim 4 is characterized in that, chimonin is 25～200 weight portions.
6. according to the preparation method of the described mangiferin dispersible tablets of claim 4, comprise following steps:
Step 1: raw material is sieved respectively, take by weighing chimonin, lactose, mannitol adds 50% crospolyvinylpyrrolidone mixing of described consumption;
Step 2: make wetting agent system soft material with 95% ethanol, cross 18～24 mesh sieves and granulate, wet granular is dry under 50～80 ℃ of conditions;
Step 3: with 16～40 mesh sieve granulate, add 50% crospolyvinylpyrrolidone, magnesium stearate, micropowder silica gel mixing of described consumption, tabletting promptly gets mangiferin dispersible tablets of the present invention.
7. according to claim 3 or 6 described preparation methoies, it is characterized in that step 1 is described sieves to crossing 100 mesh sieves.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010147681 CN101810591A (en) | 2010-03-31 | 2010-03-31 | Mangiferin dispersible tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010147681 CN101810591A (en) | 2010-03-31 | 2010-03-31 | Mangiferin dispersible tablets and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101810591A true CN101810591A (en) | 2010-08-25 |
Family
ID=42618055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010147681 Pending CN101810591A (en) | 2010-03-31 | 2010-03-31 | Mangiferin dispersible tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101810591A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893194A (en) * | 2014-04-24 | 2014-07-02 | 广西中医药大学 | Traditional Chinese medicine preparation and production method thereof |
| CN105796518A (en) * | 2016-04-08 | 2016-07-27 | 山东省中医药研究院 | Diosbulbin B dispersible tablets and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883499A (en) * | 2006-06-01 | 2006-12-27 | 广西中医学院 | Drip pills of mangiferin and preparation method thereof |
| CN1977855A (en) * | 2005-12-09 | 2007-06-13 | 海南盛科天然药物研究院有限公司 | Medicinal composition containing mangiferin and its preparing method |
| CN101229181A (en) * | 2006-09-12 | 2008-07-30 | 徐广爱 | Medicine compounds for curing diabetes and complications thereof |
-
2010
- 2010-03-31 CN CN 201010147681 patent/CN101810591A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977855A (en) * | 2005-12-09 | 2007-06-13 | 海南盛科天然药物研究院有限公司 | Medicinal composition containing mangiferin and its preparing method |
| CN1883499A (en) * | 2006-06-01 | 2006-12-27 | 广西中医学院 | Drip pills of mangiferin and preparation method thereof |
| CN101229181A (en) * | 2006-09-12 | 2008-07-30 | 徐广爱 | Medicine compounds for curing diabetes and complications thereof |
Non-Patent Citations (2)
| Title |
|---|
| 《山东中医杂志》 20080905 覃骊兰 等 芒果苷片治疗急性上呼吸道感染30例 587 1-7 第27卷, 第9期 2 * |
| 《时珍国医国药》 20090920 王志萍 等 芒果苷片体外抑菌杀虫作用的实验研究 2168页2.1.1 1-7 第20卷, 第9期 2 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893194A (en) * | 2014-04-24 | 2014-07-02 | 广西中医药大学 | Traditional Chinese medicine preparation and production method thereof |
| CN105796518A (en) * | 2016-04-08 | 2016-07-27 | 山东省中医药研究院 | Diosbulbin B dispersible tablets and preparation method thereof |
| CN105796518B (en) * | 2016-04-08 | 2018-06-12 | 山东省中医药研究院 | A kind of diosbulbin B dispersible tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100536870C (en) | Qulity control method for new compound isatis leaf preparation | |
| CN102883716B (en) | Dried plant tissue and plant tissue extract for ameliorating central nervous system degenerative diseases accompanied by learning/memory disorders, movement disorders and like, and pharmaceutical agent and food or beverage each comprising same | |
| CN101695480B (en) | Olopatadine hydrochloride dispersible tablets, preparation method thereof and quality control method thereof | |
| CN103784664A (en) | Dual-phase capsule for preventing and treating chronic pelvic inflammation and preparation method and detection method thereof | |
| CN101301425A (en) | Formulation for treating diabetes and promoting coronary circulation and quality control method | |
| CN102125533A (en) | Pazufloxacin mesylate tablet and preparation method and detection method thereof | |
| CN100389816C (en) | Tibetan medicine formulation for treating hyperlipemia, and its preparing method | |
| CN103006600A (en) | Benzenesulfonate amlodipine tablet and preparation method thereof | |
| CN106214656A (en) | The preparation of a kind of compound tablet of glycyrrhizin and test method of quality control | |
| CN102485226B (en) | Compound artemisinin piperaquine pellet and preparation method thereof | |
| CN101269097B (en) | Alstonia-leaf medicinal materials and medicament testing method for its preparation | |
| CN101485697B (en) | Bilobanone ester dispersible tablets and preparation method thereof | |
| CN101810591A (en) | Mangiferin dispersible tablets and preparation method thereof | |
| CN106018618B (en) | Escitalopram oxalate tablet composition and quality control method | |
| CN102018736B (en) | Natural indigo decoction piece and preparation method thereof | |
| CN102204999A (en) | Method for measuring content of luteolin in callicarpa nudiflora preparation | |
| CN101524398A (en) | Medical application of licorice flavonoids | |
| CN102749413B (en) | Quality detection method of traditional Chinese medicine composition for treating headache | |
| CN101513456B (en) | Chinese medicinal composition for treating headache, preparation method and quality control method thereof | |
| CN102309462A (en) | Atorvastatin calcium tablet | |
| CN102824644B (en) | High-stability sustained-release tablet prepared by using hydroxy propyl cellulose | |
| CN1957987B (en) | Medicine preparation for treating infectious diseases, preparation method, and quality detection method | |
| CN102106809B (en) | Solid preparation of clopidogrel and preparation method thereof | |
| CN103432090B (en) | Cyclovirobuxine D sublingual tablet as well as preparation method and application thereof | |
| CN105168156B (en) | A kind of Scullcap total-flavonoid dispersible tablet and its manufacturing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20100825 |